CX-5461 is currently in Phase I/II clinical trials for advanced hematologic malignancies and triple negative or BRCA-deficient breast cancer. The compound is currently administered to patients intravenously (i.v.) at low pH (3.5) due to solubility challenges. Reliance of low pH to enhance solubility of CX-5461 can adversely impact pharmacokinetics, biodistribution and therapeutic potential. We have addressed this solubility issue through a formulation method that relies on the interactions between CX-5461 and copper. Copper binds CX-5461 through the nitrogens of the pyrazine ring. Here, we describe synthesizing this copper-complexed CX-5461 (Cu(CX-5461)) within liposomes. CX-5461 was added to copper-containing liposomes and incubated at 60°C for 30 min. The pharmacokinetics of CX-5461 was assessed in mice following a single i.v. injection at 30 mg/kg. Efficacy studies were completed in multiple subcutaneous mouse xenografts as well as in a bone marrow engraftment model of acute myeloid leukemia (AML). The novel Cu(CX-5461) formulation was stable at pH 7.4 and exhibited increased plasma circulation longevity, increasing the total exposure to CX5461 by an order of magnitude. Cu (CX-5461) was more active than CX-5461 in AML models in vivo. In HCT116-B46 and Capan-1 solid tumour models that are BRCA-deficient, the Cu(CX-5461) formulation engendered activity that was comparable to that of the low pH CX-5461 formulation. We have generated the first Cu(CX-5461) formulation suitable for i.v. administration that is more efficacious than the existing low-pH formulation in pre-clinical models of AML. The Cu(CX-5461) formulation may serve as an alternative formulation for CX-5461 in BRCA-deficient cancers.
Introduction
Ribosome biogenesis is a fundamental cellular process that controls the production of ribosomes, the protein factories of the cell [1, 2] . Uncontrolled cancer cell proliferation in both hematological and solid tumours is supported by increased ribosomal RNA (rRNA) synthesis through increased activity of RNA polymerase I (Pol I). This is required to meet the abnormally high demand for protein synthesis in rapidly growing cells as proteins make up 80-90% of a cell's dry mass [3] [4] [5] [6] . In fact, deregulated rRNA synthesis is a result of altered expression of many commonly known oncogenes and tumour suppressors such as ERK, MYC, PTEN, and p53 [2, 3, 7, 8] . It can be concluded that rRNA synthesis may be one of the most important therapeutic targets in cancer cells.
While some of the most commonly used anticancer drugs (e.g. cisplatin and 5-fluorouracil) are known to have secondary mechanisms of action that lead to inhibition of rRNA synthesis, there is currently no approved drug that directly targets Pol I transcription [3, 9] . CX-5461 is a novel compound that selectively inhibits RNA Pol I by disrupting the interaction between the SL1 protein and the rDNA promoter, which is vital to the recruitment and formation of a multiprotein complex with RNA Pol I [10, 11] . It is believed that in hematological malignancies, inhibition of rRNA transcription by CX-5461 induces nucleolar stress, activating wild-type p53 which ultimately causes cancer cells to undergo apoptosis while normal cells are spared [11] . CX-5461 is also very potent against solid tumours, with half-maximal inhibitory concentrations (IC 50 ) in the nanomolar range against most cancer cell lines [10] . This potent activity is not p53-dependent [10] . Perhaps most https://doi.org/10.1016/j.jconrel.2018.07.025 Received 1 March 2018; Received in revised form 4 July 2018; Accepted 13 July 2018 interestingly, recent studies demonstrated that CX-5461 is particularly potent against BRCA-deficient cancers [12] . In this context, Xu et al. discovered that CX-5461 is acting primarily as a DNA damaging agent through stabilization of G-quadruplexes.
CX-5461 is currently in Phase I clinical trial in Australia for patients with advanced hematologic malignancies [13, 14] and is being assessed in a Phase I/II clinical trial in triple negative or BRCA-deficient breast cancer in Canada (NCT02719977). Thus far, most published pre-clinical studies associated with this compound focused on subcutaneous xenograft models with CX-5461 given either orally or intraperitoneally (i.p.). Although the compound is orally bioavailable (24% in mice) [15] , CX-5461 is being administered intravenously in the human clinical trial. CX-5461 is a sparingly soluble compound and in order to develop a formulation suitable for intravenous applications the drugs was solubilised in 50 mM sodium phosphate (pH 3.5). Such low pH phosphate buffers can engender acute toxicities due to irritation while being administered [16] . Furthermore, the injected compound may precipitate when equilibrated to physiological pH. While the compound is extremely potent in vitro, activity in vivo when given orally or i.p. is associated with either high dosages (125 mg/kg weekly) [17] or frequent dosing (25 mg/kg, 5 days a week) [15] , which could be associated with toxicity issues as well as unnecessarily high exposure to the compound as a result of formulation issues. The presence of an electrondeficient carbonyl group of the amide within the structure of CX-5461 ( Fig. 1 ) also suggests potential instability of the compound under physiological conditions. We believe that the solubility and stability issues can be addressed by reformulating CX-5461. We have demonstrated that CX-5461 coordinates with Cu 2+ or Zn 2+ via a bidentate binding motif [18] . The complexes did not have any effect on the anticancer activity of CX-5461, but the coordination with the metal ions enhanced the ligand's solubility at physiological pH [18] . To investigate the utility of Cu(CX-5461) in vivo, we have developed a novel formulation reliant on the synthesis of the copper complex within liposomes (14) . The resulting liposomal Cu(CX-5461) formulation (referred hereafter as Cu(CX-5461)) demonstrated superior efficacy in subcutaneous and intravenous models of AML and comparable therapeutic activity as CX-5461 in BRCA-deficient xenografts.
Materials and methods

Lipids and chemicals
CX-5461 was purchased from Selleck Chemicals (Houston, TX [19] . The organic solvent was evaporated under a stream of nitrogen gas and the lipid films produced were dried under vacuum to remove any residual solvent. The dried lipid films were rehydrated with 300 mM CuSO 4 at 65°C and the resulting suspension was subjected to five freeze-thaw cycles in liquid nitrogen followed by 10 extrusions through two-stacked 80 nm polycarbonate filters (Evonik Transffera Nanosciences, Vancouver) at 65°C. Un-encapsulated copper was removed by passing the liposome solution down a Sephadex G-50 size exclusion column equilibrated with SHE (300 mM Sucrose, 20 mM HEPES, and 15 mM EDTA, pH 7.4) buffer. The external buffer was then exchanged by size exclusion chromatography (SEC) into 50 mM sodium phosphate (pH 3.5).
Synthesis of Cu(CX-5461) in liposomes
CX-5461 was solubilised in 50 mM sodium phosphate (pH adjusted to 3.5 with 3% phosphoric acid) at 5 mg/mL and filter-sterilized through a 0.22 μm filter (EMD Millipore, Billerica, MA). The pre-solubilised drug was then added to the copper containing liposomes such that the final CX-5461 to liposomal lipid ratio was 0.2 (mole ratio). The solutions was incubated for 30 min at 60°C to facilitate movement of CX-5461 across the lipid bilayer where it could then react with the entrapped copper to form Cu(CX-5461); a reaction that could be detected easily by a change in the optical properties of the solution (appearance of blue colour consistent with an increase in absorbance at 610 nm). The formulation was then cooled to room temperature. The external buffer was then exchanged to HBS (20 mM HEPES, 150 mM NaCl, pH 7.4) via SEC and the final formulation was concentrated to the desired concentration using tangential flow filtration. The size and polydispersity of the resultant formulation was assessed using the ZetaPALS particle sizer (Brookhaven Instruments Corp., Holtsville, NY). Drug concentration was determined via UV-Visible Spectroscopy at 288 nm using the Agilent 8453 UV-visible Spectrophotometer (Santa Clara, CA) and liposomal lipid concentration was determined by measuring [3H]-CHE by liquid scintillation counting (LS6500 Multipurpose Scintillation Counter; Beckman Coulter, Mississauga, Ontario).
Dose-range finding and pharmacokinetic studies
To determine the maximum tolerated dose for a multiple dose schedule, CX-5461 or Cu(CX-5461) was administered intravenously into 10-12 weeks old female Rag2-M mice using a Q4Dx3 schedule (n = 4). A dose was considered tolerated when the mice survived 14 days following the final injection without displaying unacceptable side effects. The health status of the animals was monitored following an established standard operating procedure. In particular, signs of ill health were based on body weight loss, change in appetite, and behavioral changes such as altered gait, lethargy and gross manifestations of stress. When signs of severe toxicity were present, the animals were terminated (isoflurane overdose followed by CO 2 asphyxiation) for humane reasons. Necropsies were performed on all animals terminated for humane reasons. As indicated, the surviving animals were monitored for two weeks (14 days) after administration of the last dose and full necropsies were completed on all treated mice at that time to assess changes in tissue/organ appearance.
Pharmacokinetic studies with CX-5461 or Cu(CX-5461) were completed in 6-8 weeks old female RAG2-M mice (n = 4 per time-point).
The Cu(CX-5461) formulation was prepared using liposomes labelled with the non-exchangeable and non-metabolized radioactive tracer [ 3 H]-CHE, as described above, such that the specific activity was 95,574 DPM/μmole total lipid. All mice received a single dose of 30 mg/kg CX-5461 or Cu(CX-5461) intravenously (i.v.) and blood was obtained by saphenous bleed 30-min post-injection and by cardiac puncture for the remaining time points. Whole blood was collected into EDTA coated tubes kept on ice and centrifuged (Beckman Coulter Allegra X-15R) at 1500 x g for 15 min at 4°C. Plasma was collected and placed into a separate tube prior to assaying for lipid, copper and CX-5461. The liposomal lipid concentration ([ 3 H]-CHE) in plasma was measured via liquid scintillation counting. CX-5461 and copper concentrations were measured using high performance liquid chromatography (HPLC) and flameless atomic absorption spectroscopy (AAS) methods, respectively.
Atomic absorption spectroscopy
Concentrations of copper in plasma and tumour homogenates were measured by flameless AAS. Samples were diluted in 0.1% nitric acid and analyzed using the AAnalyst 600 Atomic Absorption Spectrometer (Perkin Elmer Life Sciences, Waltham, MA). Briefly, samples were dried at 110°C for 30s, heated (45 s) to 130°C, ashed at 1200°C for 30s, and atomized and cleaned at 2000°C (5 s) and 2450°C (4 s), respectively.
HPLC analyses
CX-5461 concentration was determined using the HPLC with a Luna 5 μ C18 (2) 100 A (150 × 4.6 mm) column and C18 Symmetry shield guard column (Waters, Mississauga, ON). An isocratic elution with mobile phase consisting of 45% of 0.1% TFA (trifluoroacetic acid) in water and 55% of 0.1% TFA in methanol was used. Standard curves (ranged from 0.5 to 5 μg/mL) were prepared in plasma obtained from untreated mice; where 3% acidified methanol was used as the extraction solvent. Samples (5 μL) were injected onto the column and eluted at a flow rate of 1 mL/min. All standards and samples were kept at 4°C prior to injection and the column temperature was maintained at 35°C. CX-5461 concentrations were measured using the Waters 2695 Separation Module attached to the Waters 996 PDA detector set at 300 nm. The retention time for CX-5461 was 6 min. Measurements were done in triplicates.
Efficacy of Cu-CX5461 in s.c. and systemic MV-4-11 xenograft models
For the s.c. model, female RAG2-M mice were inoculated sc with 1 × 10 6 MV-4-11 cells and treatment was initiated when the average tumour size for each treatment group following randomization ranged between 50 and 100 mm 3 . Mice were treated with 30 mg/kg free or Cu (CX-5461) injected i.v. every 4th day for three times (Q4Dx3 schedule; n = 7). Mice were monitored daily, and body weight measurements as well as signs of stress (e.g. ruffled coat, lethargy, etc) were used as indicators of toxicities. Tumour size was measured using an electronic caliper (Mitutoyo Corp.) and the tumour volumes were calculated using the equation (l x w 2 )/2. Animals with ulcerated tumours or whose tumours exceeded 800 mm 3 were euthanized via cardiac puncture.
Animals that had tumours < 50 mm 3 at the time of the first treatment were excluded from the analysis. The final analysis consisted of six animals per treatment group. For the systemic model, male NRG mice were pre-treated (i.p.) with 100 mg/kg cyclophosphamide for 2 consecutive days, followed by a 48-h rest prior to i.v. injection of 5 × 10 6 MV-4-11 cells as described by others [20, 21] . Treatment began on day 21 when approximately 1.0-1.5% of the bone marrow cells are shown to be of human origin, as determined by staining with anti-human CD45 antibody and flow cytometric analysis ( Fig. S1 and Supplemental Methods). The mice were treated i.v. with 30 mg/kg of free or Cu(CX-5461) (Q4Dx3 dosing schedule). When the animals displayed signs of hind limb paralysis or became moribund, they were euthanized and the following day was recorded as the survival time. . Animals were treated with 30 mg/kg of CX-5461, Cu(CX-5461) or the nanoparticle vehicle at the equivalent lipid dose every 4 days for a total of three doses (Q4Dx3). The mice were monitored and tumour volumes were measured as described above. Animals with tumour volumes that exceeded 180 mm 3 on the day of the first dose were excluded from the HCT116 studies (n = 6-8 per treatment group analyzed) while animals with tumour volumes < 50 mm 3 at the time of the first treatment was excluded from the Capan-1 data analysis (n = 7 per group analyzed).
Statistical analyses
All data were plotted using Prism 6.0 (GraphPad Software). Tumour growth curves were plotted for each treatment group until there were at least 4 animals remaining per group. Tumour volumes were compared via one-way ANOVA followed by Tukey multiple tests correction. The comparison was performed at one time point: the day when the last data point was plotted for the untreated group. The Log-rank (MantelCox) test was used to compare pairs of Kaplan-Meier survival curves. Pvalues < .05 were considered statistically significant.
Results
Characterization of Cu(CX-5461) formulation
We recently reported that CX-5461 can bind copper (Cu 2+ ) and Zinc (Zn 2+ ) [18] . More specifically, it was demonstrated that pre-incubation of CX5461 with CuSO 4 or ZnSO 4 aided solubilization of the compound at pH 7 and that formation of the Cu/Zn-CX5461 complex did not alter the anti-cancer activity of CX-5461 [18] . The proposed structure of Cu (CX-5461) is shown in Fig. 1 . Previously, we showed that synthesis of metal complexes could take place inside liposomes, thus providing a simple method to prepare various metal complexes for in vivo studies [22, 23] . Using this method, we generated the first nanomedicine formulation of CX-5461. Cu(CX-5461) was synthesized within 100 nm DSPC/Chol liposomes. The formulation was characterized and the results are summarized in Fig. 2 .
Copper-containing liposomes were prepared by rehydrating lipid films in 300 mM CuSO 4 . CX-5461 was added to achieve a final drug-tolipid ratio of 0.2. As shown in Fig. 2A , formation of Cu(CX-5461) was time and temperature-dependent. > 98% of the added CX-5461 became associated with the copper-containing liposomes within 10 min when incubated at 60°C. Cu(CX-5461)complex formation was evident by a colour change that was easy to observe after drug loading (Fig. 2B) . When the incubation temperature was decreased, the rate of Cu(CX-5461) formation was reduced, with < 10% of the added CX-5461 associated with liposomes after 30 min at 4°C. As shown in Fig. 2C and D, the association of CX-5461 with the liposomes was copper-dependent, albeit a measurable level of CX-5461 evidently partitioned into the membrane in the absence of copper. The data in Fig. 2D show CX-5461 and copper levels plotted after subtraction of the partitioned drug. These results suggest a linear relationship with a slope of 1.16 ± 0.14, consistent with the idea that the copper to CX-5461 ratio inside the liposome was approximately 1:1. The resultant formulation exhibited a mean diameter of 85 nm (+/− 20 nm) with approximately 0.1 polydispersity. Furthermore, this formulation can be stored at 4°C for at least 21 days with no significant change in the level of liposome-associated drug, particle size, or polydispersity ( Fig. 2E and F) .
Plasma elimination of Cu(CX-5461) and CX-5461
The maximum feasible dose of CX-5461 was determined to be 50 mg/kg based on limitations in aqueous solubility and the Fig. 2 . Synthesis of a stable Cu(CX-5461) formulation. Synthesis of Cu(CX-5461) complexes in lipid vesicles is temperature-dependent (A). Optimal rate of Cu(CX-5461) formation is achieved at 60°C, where 100% of the drug when added at a drug-to-lipid ratio of 0.2 become associated with the vesicles within 10 min. The coordination between copper and CX-5461 can be visualized in B. CX-5461 can only be solubilised (clear and transparent) at low pH. Copper sulfate-containing liposomes can be prepared and the external buffer of the liposomes can be exchanged to a low pH buffer. CX-5461 can then be loaded into the copper-containing liposomes (white), resulting in the formation of a blue formulation where the Cu(CX-5461) complex is encapsulated. The external buffer is then exchanged to HBS (pH 7.4). CX-5461 association with lipid vesicles is dependent on having encapsulated copper and the amount of Cu-CX5461 formed increases with increasing copper content within the vesicles (C). An analysis of CX-5461 and copper in the vesicles suggests a linear regression with a slope of 1.16, consistent with the complex forming at a 1:1 M ratio (Cu 2+ to CX-5461) (D). The resulting formulation is stable for at least three weeks (at 4°C) based on measurements of Cu(CX-5461)-to-lipid ratio (E), particle size, and polydispersity of the solution (F). All data are plotted as mean ± SEM. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) requirement to use a low pH (3.5) phosphate buffer to dissolve the compound in aqueous solutions. Using a Q4Dx3 dosing schedule, the maximum tolerated dose (MTD) of CX-5461 was 30 mg/kg (pH 3.5) when injected i.v.. For comparison purposes, the studies to define plasma elimination were completed at 30 mg/kg for both CX-5461 and Cu(CX-5461). Our analytical method was not able to differentiate between CX-5461 and Cu(CX-5461); hence, the same HPLC method was used to estimate plasma concentrations of CX-5461. The presence of copper did not interfere with the analytical assay. Following i.v. administration of the low pH formulation, CX-5461 was eliminated very rapidly from the plasma compartment, as shown in Fig. 3 . Greater than 96% of the injected drug is eliminated within the first time point collected (1 h), while almost 90% of the injected Cu(CX-5461) was still retained in the plasma compartment. Approximately 10% of the injected CX-5461 was detected in circulation at 24 h following injection of the Cu(CX-5461). Based on area under the curve (AUC) estimations, there was a 19-fold increase in total drug exposure (AUC = 249.1 μg-hr/mL for CX-5461 and 4708.6 μg-hr/mL for Cu(CX-5461)) following administration of the Cu(CX-5461) formulation. As shown in Fig. 3B -C, the plasma lipid and copper concentrations decreased over the 48 h period. However, the copper/lipid ratio was maintained at approximately 0.2 while the plasma drug/lipid ratio decreased over time (Fig. 3D) . These results suggest that the Cu(CX-5461) complex dissociated following administration and copper free CX-5461 was released from the liposomes over time.
The Cu(CX-5461) formulation is more efficacious than the free drug in pre-clinical models of acute myeloid leukemia (AML)
We evaluated the activity of CX-5461 and Cu(CX-5461) in two different models derived following injection of MV-4-11 cells: a subcutaneous xenograft and a bone marrow engraftment model. The latter model is more aggressive and resembles more closely the systemic disease in humans. The MV-4-11 cell line was chosen because the initial clinical trials focused on the use of CX-5461 to treat hematologic malignancies. In the subcutaneous model, tumour growth in animals treated with 30 mg/kg of CX-5461 (Q4Dx3) was similar to the untreated group (Fig. 4A) . A significant delay in tumour growth was observed in animals treated with 30 mg/kg Cu(CX-5461). On Day 37, when the first animal in the untreated group reached its humane endpoint, the mean tumour volumes for the untreated, CX-5461, and Cu (CX-5461)-treated groups were 723 ± 108, 614 ± 91, and 239 ± 55 mm 3 (mean ± SEM), respectively. There was no statistically significant difference between the untreated and the CX-5461-treated group. The difference between the CX-5461 and Cu(CX-5461) tumour volumes on Day 37 was statistically significant (adjusted p- Fig. 5 . Cu(CX-5461) is efficacious against BRCA-deficient xenograft models. The tumour growth curves plotted in (A) shows that the vehicle and the two CX-5461 formulations had no effect on wild-type HCT116 subcutaneous tumours. Both CX-5461 and Cu(CX-5461) were effective against BRCA-deficient HCT116-B46 and Capan-1 subcutaneous tumours (B). Although Cu(CX-5461) appear to be more efficacious, the difference compared to CX-5461 was not statistically significant in both models. The tumour volumes on day 36 and day 48 are plotted for HCT116-B46 and Capan-1, respectively. The reduced tumour volumes observed following treatment with either formulation was significant when compared to the untreated group in both models (*p < .05). All data are plotted as mean ± SEM and tumour volumes were compared using one-way ANOVA followed by Tukey adjustments. value = .0118; Fig. 4B ).
In the bone marrow engraftment model, mice pre-treated with cyclophosphamide were inoculated with 5 × 10 6 MV-4-11 cells (Fig. 4C ).
All mice were treated 21 days after cell inoculation (when the engraftment was approximately 1.0-1.5%; Supplementary Fig. 1 ) with 30 mg/kg of either CX-5461 or Cu(CX-5461) (Q4Dx3). The median survival for the untreated, CX-5461, copper liposome control, and Cu (CX-5461) were 45, 49, 49, and 51 days. The increase in median survival was 8.9% for both the CX-5461 and copper liposome controls and these differences were not significant compared to the untreated controls. Treatment with Cu(CX-5461) resulted in a 13% increase in median survival and the results were significantly different when compared to the untreated (p = .0046), copper liposome control (p = .01) and the CX-5461-treated (p = .0318) groups. These results suggest that the Cu(CX-5461) formulation is more efficacious than the existing CX-5461 formulation in the AML models.
3.4. The cu(CX-5461) formulation may serve as an alternative formulation for CX-5461 in BRCA-deficient cancers
We assessed the activity of Cu(CX-5461) in two HCT116 colorectal carcinoma and one pancreatic ductal adenocarcinoma s.c. xenograft models. The HCT116 studies consisted of two isogenic cell lines, one of which is a BRCA2 knockout cell line (B46). The tumour growth curves shown in Fig. 5A -B demonstrates that CX-5461, administered as the low-pH formulation or as the Cu(CX-5461) formulation, is effective against the BRCA2-deficient model, which is in contrast to the wild-type model where the treatment groups had no impact on tumour development. On day 36, the difference in tumour volumes in the HCT116-B46 model is statistically significant between the untreated and CX-5461-treated groups (p = .0374) and between the untreated and Cu(CX-5461)-treated groups (p = .0134; Fig. 5C ). There was no statistically significant difference between the two formulations of CX-5461. Similarly, in the Capan-1 BRCA2-deficient model, the two formulations for CX-5461 displayed comparable therapeutic activity and the average tumour volume in the CX-5461 and Cu(CX-5461) groups were statistically different compared to the untreated group (p-value = .0007 and 0.0069, respectively) ( Fig. 5B-C) . There appeared to be a trend for delayed tumour development when mice were treated with Cu(CX-5461) compared to CX-5461; however, the differences were not statistically significant. These data suggest that the Cu(CX-5461) formulation is equally effective against BRCA2-deficient cancers as the existing low pH formulation of CX-5461.
Discussion
CX-5461 is the first selective inhibitor of RNA polymerase I transcription that is being evaluated in phase I clinical trials in Australia for the treatment of advanced hematologic malignancies [13, 15] . In addition, it has recently been shown that CX-5461is a G-quadruplex stabilizer that exhibits enhanced toxicity in the context of BRCA-deficient cancer cell lines. These results have led to initiation of clinical trials (Phase I/II) in Canada evaluating the activity in breast cancer patients some of which carry BRCA mutations. Given the potential use of CX-5461 i.v. to treat a range of solid and hematologic cancers, we decided to explore the efficacy of intravenously administered Cu(CX-5461). According to the chemical structure (Fig. 1A) , CX-5461 has multiple potential copper-binding moieties. We have characterized the chemical structure of the Cu(CX-5461) complex and confirmed that copper complexation increases the aqueous solubility of CX-5461 [18] .
Although complexation with copper allows CX-5461 to be prepared at physiological pH, the copper complex may readily dissociate upon i.v. injection as copper is known to interact with plasma components such as ceruloplasmin [24] . We have therefore developed a formulation where the Cu(CX-5461) is synthesized within liposomes; thus, protected from rapid degradation and the potential for precipitation in vivo. The use of this strategy has two advantages: 1) once the Cu(CX-5461) complex is formed within the liposomes, the external buffer can be exchanged to one that is most suitable for i.v. administration; and 2) the pharmacokinetics and biodistribution of the Cu(CX-5461) formulation becomes dependent on destabilization of the copper complex as well as the rate at which CX-5461 dissociates from the liposome following administration. In other words, the pharmacokinetics and biodistribution of CX-5461 can be altered by changing the composition of the liposomes to ultimately achieve optimal therapeutic activity [25] . Our results demonstrate that Cu(CX-5461) can form efficiently in coppercontaining liposomes; where formation of the Cu(CX-5461) complex is evident through a colour change (solution changes from white to blue). The amount of Cu(CX-5461) encapsulation is dependent on the amount of copper within the liposomes and conditions can be defined to ensure that 100% of the CX-5461 added to the copper-containing liposomes becomes liposome-associated. The resulting formulation is stable for at least three weeks in buffered saline at pH 7.4, with no significant changes in particle size (100 ± 20 nm) or polydispersity (≤0.1).
The circulation lifetime of CX-5461 is extended, when compared to the existing low-pH formulation that was rapidly eliminated from the plasma compartment. It is also important to note that the pharmacokinetics of liposomal lipid and copper were comparable while the drugto-lipid ratio was reduced over time, suggesting that the copper remains within the liposomes while copper-free CX-5461 is being released. As mentioned earlier, the copper ion does not contribute to the therapeutic activity of CX-5461 [18] and our data suggest that copper is not released from the liposomes in the plasma compartment. It is also important to note that all of our current and previous studies have demonstrated that the copper liposomes are not therapeutically active and do not contribute to toxicity issues [26] . Specifically, at necropsy following the efficacy studies presented here, no vehicle or Cu(CX-5461)-specific toxicity was observed. It is important to note that although copper is an essential trace metal for human physiology, acute and chronic toxicities could result from oral or parenteral administration [27] . Acute copper toxicity typically affects the gastrointestinal tract, liver, and kidneys while chronic copper toxicity causes hepatic necrosis followed by haemolysis as observed in dogs, cattles, and sheeps [27] . In mice, the LD 50 of CuSO 4 given intraperitoneally was reported to be 33 mg/kg [28] . While it can be speculated that direct i.v. injection of CuSO 4 at high concentrations could induce copper poisoning in rodents and in humans, there is little known about the impact of i.v. administration of CuSO 4 [29] . Furthermore, the Cu(CX-5461) formulation presented here result in a copper dose that is < 5 mg/kg and this copper is encapsulated within liposomes and appears stably associated at least based on the plasma data. As demonstrated in our pharmacokinetics results, plasma copper levels decreased over time and the copper-tolipid ratio was maintained throughout the duration of the study, suggesting that copper remained associated with the liposomes. These data suggest that copper was not released and it could be speculated to accumulate in the liver and spleen [30] . Although toxicities in the liver and spleen were not apparent in our studies, further exploration of the distribution of copper upon i.v. administration of a copper-containing product is warranted when an optimal CX-5461 formulation that would be selected as a lead candidate for development. In this case, the potential acute and chronic toxicities will be identified following treatment at clinically relevant dosages. It should be noted that in humans, individuals that have Wilson's disease or any history of copper metabolism disorder will likely be more susceptible to copper poisoning. Also, with individuals who have normal copper metabolism, copper is less toxic relative to other clinically approved metal-based chemotherapeutics, particularly platinum-based agents such as cisplatin, carboplatin, and oxaliplatin. Hence, enormous efforts have been placed on developing copper-based therapeutics to replace or reduce the use of platinum as anticancer agents and we are particularly interested in developing copper compound complexes as a brand new class of therapeutics [31, 32] . Recently, a copper-containing liposomal product Vyxeos®, initially developed at BC Cancer and commercialized by Celator Pharmaceuticals, was approved for the treatment of acute myeloid leukemia. As with most chemotherapeutics, the dose limiting toxicities associated with Vyxeos® were attributed to the potent chemotherapeutics and not the copper content [33, 34] . As a precaution, patients susceptible to copper metabolism disorders were excluded from their clinical trials. Based on recently reported data on the phase I clinical trial with CX-5461, photosensitivity appears to be the main toxicity observed when this drug is given intravenously as a low pH formulation [35] . It will be important in future studies to determine whether CX-5461 or the copper content in the final Cu(CX-5461) formulation will contribute to this dose limiting toxicity or introduce a new toxicity.
Since CX-5461 exposure (time and concentration) is increased significantly following administration of Cu(CX-5461), we speculated that Cu(CX-5461)would be more active against tumour-bearing xenografts based on previous experiences with other liposomal formulations [36, 37] . We assessed whether increases in CX-5461 exposure time affected therapeutic activity the drug and demonstrated that increasing the drug exposure time did not increase its therapeutic activity in vitro (Fig. S2) . These results are consistent with studies completed by another group demonstrating that transient exposure to CX-5461 was sufficient to elicit cell death in leukemia cells [38] . These data suggest that circulation lifetime may not be as important to CX-5461 activity compared to some other chemotherapeutics (e.g. vincristine, topotecan, irinotecan, etc.) but the Cu(CX-5461) formulation will ensure that cancer cells are exposed to higher concentration of the drug over time when compared to the low pH formulation. The results from both s.c. and bone marrow engraftment MV-4-11 models suggest that the Cu(CX-5461) formulation was more efficacious than the low pH formulation when administered at comparable doses.
It has been recently demonstrated the CX-5461 is particularly active against BRCA-deficient cancers [12] . For this reason, we also evaluated the activity of the CX-5461 and Cu(CX-5461) formulations in HCT116 wild-type and HCT116-B46 BRCA-knockout xenografts as well as the Capan-1 model which is well-characterized to be BRCA-deficient [39] [40] [41] . Our results from the HCT116 models are consistent with previous studies by Xu et al.; studies that demonstrated that CX-5461 was not effective against HCT116-WT. Both formulations were, however, effective when tested in the HCT116-B46 xenograft model. Similarly, the two formulations were effective in mice bearing sc Capan-1 tumours. Further studies are required to gain a better understanding of why the Cu(CX-5461) formulation was more effective in the sc MV-4-11 model, but not the sc Capan-1 or HCT116-B46 xenograft models. This may be a consequence of differences in the EPR effect within these models [42] .
Importantly, based on the data we have collected, the Cu(CX-5461) formulation may serve as an alternative formulation for CX-5461 which is suitable for i.v. administration at physiological pH and may enhance therapeutic activity in the absence of toxicity associated with the low pH CX-5461 formulation. While the current study focused on comparing one Cu(CX-5461) formulation with the existing free CX-5461 formulation, future studies should include formulations of Cu(CX-5461) prepared with other lipid compositions in order to fully elucidate how the formulation strategy impacts antitumor activity in vivo. Importantly, it is well understood that the most effective treatments of cancer require combinations of at least two drugs and this is unlikely to change in the future. The inventors of CX-5461 have already demonstrated that CX-5461 can be combined with inhibitors of the PI3K/AKT/mTOR pathway to delay relapse and extend survival in mice bearing MYC-driven tumours [43] . On the other hand, we believe that there is potential to use CX-5461 in combination with topoisomerase I inhibitors based on 1) studies in yeasts suggesting synthetic lethal genetic interactions between topoisomerase I inhibition and components important for rRNA transcription [44, 45] , 2) studies in Xenopus oocytes indicating high topoisomerase I activity during rRNA transcription [46, 47] , and 3) studies demonstrating that rRNA transcription is most active during the S/G2 phase of the cell cycle when topoisomerase I inhibitors are also most effective (3) . With recent studies suggesting CX-5461 being particularly active against BRCA-deficient cancers, this compound may also be effective when used in combination with platinum agents. Therefore, we believe that the liposomal Cu(CX-5461) formulation described here will be of great interest for the clinic when developed as a combination product as demonstrated by the recent success of VYXEOS® for the treatment of leukemia which consists of cytarabine and daunorubicin provided as a single liposomal drug product at a fixed 5:1 M ratio of the two components, respectively [48] [49] [50] [51] .
